SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (24428)8/12/1998 10:20:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Robert, Not sure on money spent by SRGN, but $150 million comes to mind (I think that one of the Bear Stearns or H&Q? reports had given a fairly hard number).



To: Machaon who wrote (24428)8/12/1998 10:33:00 PM
From: Henry Niman  Respond to of 32384
 
From June 4, 1998 BARS report:

This deal was primarily driven by Seragen's lead compound, Ontak, which is under
FDA consideration to treat cutaneous T-cell lymphoma (CTCL).
- Seragen has spent over $200 million in the development of this technology.
- Eli Lilly has spent another $20 million on Ontak.
- We believe that Ontak is a late stage product that fits well in Ligand's cancer
franchise, specifically to treat CTCL.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News